Agathos Biologics

What Agathos Biologics does

Agathos Biologics is a Fargo, North Dakota-based biotechnology company founded in April 2021 by James Brown, Michael Chambers, and John Ballantyne, all former Aldevron and REGENXBIO executives. The company develops proprietary mammalian cell lines, principally the AE1-BHK line (BHK-21 stably transfected with adenoviral E1) and its suspension-adapted derivative AE1-BHK-S, as ethical alternatives to HEK293 and PER.C6 for recombinant adeno-associated virus (rAAV) production. Agathos monetizes through four streams: (1) free distribution of AE1-BHK for research use under a Limited Use Label License, with commercial use requiring a separate license; (2) off-the-shelf AAV control and reporter vectors (AAV2, AAV5, AAV6, AAV8, AAV9 with eGFP or mCherry) priced at $325 per unit through direct e-commerce; (3) custom rAAV production services using triple transfection in AE1-BHK, with the first commercial sale completed to CRO/CMO Genovac in March 2024; and (4) analytical services including high-content imaging and digital PCR using QIAGEN QIAcuity instrumentation. The company operates from a 10,000 square foot research facility in Fargo, has received $1.2 million in North Dakota Bioscience Innovation Grants across 2021 and 2023, has pending patent applications on its cell line technologies, and targets genetic medicine researchers, gene therapy developers, and CRO/CMOs with an ethical-sourcing value proposition that distinguishes it from incumbent HEK293-based suppliers.

Name

Agathos Biologics

Legal name

Agathos Biologics

Website

https://agathos.bio

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Agathos Biologics is a Fargo-based biotechnology company that develops and commercializes proprietary ethical mammalian cell lines (AE1-BHK and AE1-BHK-S) as alternatives to HEK293 for recombinant AAV production, serving gene therapy developers, CRO/CMOs, and academic researchers.

Ownership category

akta.pro rank

Product category

Biologics Manufacturing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK)

Keywords

• Cell line development
• Viral vector production
• Biologics manufacturing
• Analytical testing services
• Gene therapy materials

Headquarters

HQ city

Fargo

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. AAV Product Sales: Sale of recombinant adeno-associated virus (rAAV) control and reporter vectors in various serotypes (AAV2, AAV5, AAV6, AAV8, AAV9) with fluorescent reporters (eGFP, mCherry). Products sold at $325 per unit.
2. AE1-BHK Cell Line Licensing: Free distribution of AE1-BHK cells for research use under Limited Use Label License (LULL). Commercial use requires separate commercial license agreement.
3. Custom rAAV Production Service: Fee-for-service rAAV production using client's transgene sequence in AE1-BHK cell line via triple transfection. First sale recorded to Genovac in March 2024.
4. Analytical Services: Fee-based analytical testing services including high-content imaging and digital PCR for life science researchers and biotechnology companies.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Agathos Biologics develops and supplies proprietary mammalian cell lines (AE1-BHK and suspension-adapted AE1-BHK-S) for ethical recombinant adeno-associated virus (rAAV) production, provides custom rAAV manufacturing services using triple transfection, sells off-the-shelf AAV control/reporter vectors across multiple serotypes (AAV2, AAV5, AAV6, AAV8, AAV9) with fluorescent reporters, and offers analytical services including high-content imaging and digital PCR for life science researchers and biotechnology companies.

Product overview

Agathos Biologics is a biotechnology company operating as 'The Good Science Company' that provides ethically-sourced cell lines, viral vector production services, and analytical services for genetic medicine research and biomanufacturing. The core product is the AE1-BHK cell line (and its suspension-adapted variant AE1-BHK-S) for recombinant adeno-associated virus (rAAV) production, which offers an ethical alternative to HEK293 and PER.C6 cell lines. The company also offers custom rAAV production services using the AE1-BHK cell line, a suite of AAV control and reporter vectors in multiple serotypes (AAV2, AAV5, AAV6, AAV8, AAV9 with eGFP and mCherry fluorescent reporters), and analytical services including high content imaging and digital PCR. Additional research cell lines include GH329 (HeLa-based) and BHK-[wt E1]. Products are provided for research use with expansion into regulated biomanufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• AE1-BHK Cell Line Proprietary mammalian cell line developed by stable transfection of BHK-21 (C-13) with the adenoviral E1 gene using hygromycin selection. Designed for recombinant adeno-associated virus (rAAV) production and other biomanufacturing applications, providing an ethical alternative to HEK293 for gene therapy researchers, biotechnology companies, and CRO/CMOs. Provided free for research use under a Limited Use Label License (LULL); commercial use requires separate commercial licensing.
• AE1-BHK-S Cell Line Suspension-adapted variant of the AE1-BHK cell line, adapted for serum-free suspension culture to enable scalable rAAV biomanufacturing for industrial and clinical-scale production needs of biotechnology companies and CRO/CMOs.
• AAV Reporter Vectors (AAV2, AAV5, AAV6, AAV8, AAV9 with eGFP and mCherry reporters) Off-the-shelf recombinant adeno-associated virus (rAAV) control and reporter vectors across serotypes AAV2, AAV5, AAV6, AAV8, and AAV9 with CMV-eGFP or CMV-mCherry fluorescent reporters and SV40 polyadenylation signal. Sold at $325 per unit through company e-commerce for life science researchers and biotechnology companies requiring standardized AAV controls for research applications.
• Custom rAAV Production Service Fee-for-service custom manufacturing of recombinant adeno-associated virus (rAAV) using the proprietary AE1-BHK cell line via triple transfection. Company assists with expression cassette design containing the client's transgene of interest. Serves gene therapy developers, CRO/CMOs, and biotechnology companies requiring ethical cell line alternatives for viral vector production. Pricing is quote-based; first commercial sale recorded to Genovac in March 2024.
• Analytical Services (High-Content Imaging and Digital PCR) Advanced fee-based analytical testing services including high-content imaging (immunohistochemistry, immunofluorescence, signaling pathway analysis) and digital PCR (dPCR) using QIAGEN QIAcuity instrumentation for nucleic acid quantification, mutation analysis, viral vector titer determination, and pathogen detection. Serves life science researchers and biotechnology companies; first of its kind in the Fargo region.
• BHK-[wt E1] Cell Line Research-stage cell line based on BHK-21 transformed with plasmid containing wild-type E1 gene of adenovirus, demonstrated to produce rAAV using standard triple transfection. Subject of provisional patent applications.
• GH329 Cell Line Research-stage cell line based on HeLa transformed using a modified version of the adenovirus E1 gene, shown to produce rAAV using triple transfection. Previously developed for recombinant adenovirus production; part of Agathos's broader cell line research portfolio.

Quantifiable outcome

• First sale of rAAV produced using triple transfection in a cell line other than HEK293
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• GenovaccoreStrategic or Co-development Partner · 6 March 2024Agathos completed first commercial sale of rAAV produced using AE1-BHK cell line to Genovac. Genovac is a contract research and manufacturing organization (CRO/CMO) specializing in antibody discovery and production. Agathos produced rAAV with a Genovac-provided transgene sequence using triple transfection in AE1-BHK. Genovac will also receive AE1-BHK cell line samples for evaluation of use in recombinant antibody and protein production.
• QIAGENcoreTechnology or IntegrationAgathos exclusively uses QIAGEN QIAcuity instrumentation and assays for digital PCR services. Agathos collaborated with QIAGEN in mycoplasma and recombinant adeno-associated viral vector (rAAV) assay testing and validation. Agathos participated in QIAGEN-hosted roundtable discussion on viral vector integrity analysis.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Catalent: Large-scale CDMO with dedicated cell and gene therapy services including AAV and lentiviral vector manufacturing. Represents the type of scaled incumbent Agathos would need to displace or partner with for clinical/commercial AAV supply contracts.
• Lonza Cell & Gene Technologies: Global CDMO offering cell and gene therapy manufacturing services including viral vector production. Comparable as an end-to-end CDMO competing for the same customer relationships Agathos targets for custom rAAV production.
• Charles River Laboratories (Cobra Biologics): Following the Cobra Biologics acquisition, Charles River offers viral vector and plasmid CDMO services for cell and gene therapy. Direct CDMO peer to Agathos' custom rAAV service offering.
• Thermo Fisher Scientific (Patheon/Brammer Bio): Global CDMO through its Brammer Bio viral vector services business, providing AAV and lentiviral manufacturing for gene therapy. Directly comparable as an established large-scale rAAV CDMO peer.
• Aldevron (Cytiva/Danaher): Agathos founders co-founded Aldevron, which became the dominant CDMO for plasmids, proteins, and viral vectors used in gene therapy before being acquired by Danaher for $9.6B. Aldevron is the closest large-scale analog for Agathos' rAAV production service and AE1-BHK licensing model.

Direct peers

• CellGenix: Supplier of GMP-grade cell culture reagents and viral vector manufacturing services for cell and gene therapy. Comparable to Agathos in providing both cell-line-derived production tools and custom manufacturing services.
• Addgene: Non-profit repository distributing cell lines, plasmids, and viral vectors to researchers globally. Comparable to Agathos' free AE1-BHK research-use distribution model and AAV vector catalog for academic customers.
• Cobra Biologics (now Charles River): Specialist viral vector and plasmid DNA CDMO serving gene therapy developers. Directly comparable in service model (custom AAV/lentiviral production) to Agathos' rAAV production service.

Others

• QIAGEN: Existing technology partner of Agathos for digital PCR (QIAcuity) services, with collaboration on viral vector integrity assays. Comparable as a life sciences tools and assay provider serving gene therapy analytical needs adjacent to Agathos' analytical services offering.
• REGENXBIO: Clinical-stage gene therapy company developing AAV-based therapeutics, where Agathos' CEO was the second employee. Comparable as a buyer/end-user of rAAV production services and represents the customer archetype Agathos targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/agathosbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agathos Biologics